Navigation Links
Gene Therapy Holds Promise for HIV
Date:2/15/2009

But research is preliminary and more trials are needed, study says

SUNDAY, Feb. 15 (HealthDay News) -- Researchers are reporting promising results from the largest clinical trial of gene therapy for HIV patients. The findings, while encouraging, need to be replicated and more research must be done before an effective new treatment arrives, experts said.

"We know it works, but we need to make it better before we launch a later study," said study lead author Dr. Ronald Mitsuyasu, director of the University of California, Los Angeles Center for Clinical AIDS Research and Education.

Existing treatments work fairly well for many people with HIV, the virus that causes AIDS. But patients have to take expensive drugs for their entire lives, and side effects can be significant.

Gene therapy is considered a possible alternative to drug treatment. Researchers hope to fight the virus by inserting a gene or genes into the body of an infected individual.

Last week, the New England Journal of Medicine reported a case that showed the potential for gene therapy and HIV. According to the journal, the body of a man in Germany with AIDS became free of the virus after he received a bone marrow transplant from a man with a gene that made him virtually immune to HIV. The treatment may not be a cure because the AIDS virus can become undetectable while still remaining in the body.

In the new study, researchers focused on a molecule that targets the AIDS virus. The scientists recruited 74 HIV-positive people and intravenously gave them either the molecule -- called OZ1 -- via blood stem cells, or a placebo. The patients then cycled on and off their HIV drugs so the researchers could see if the virus rebounded.

The patients who got the gene therapy treatment had a "modest decline" in the level of virus in their bodies, Mitsuyasu said. After 100 weeks, immune systems were also stronger in those patients who received the gene therapy vs. those who did not. In fact, some patients are doing so well that they haven't returned to drug treatment, Mitsuyasu said.

The findings were published online Feb. 15 in the journal Nature Medicine.

The study was a "phase II" trial, meaning that a third study would be necessary before the treatment could be approved.

There's more to be done, however, Mitsuyasu said.

"We need to figure out how best to perfect this approach. There are a lot of things that we could potentially do," he said. But in the big picture, the research represents "the first clear indication in a randomized and controlled study that there is a biologic effect of gene therapy" for HIV, he added.

The new approach holds promise, said Rowena Johnston, vice president of research at the Foundation for AIDS Research (amFAR) in New York City.

"One of the striking successes of this particular approach is its apparent safety, which is no small matter given the history so far of gene therapy interventions," she said. "Gene therapy will probably represent an exciting new frontier that will receive increasing attention in the coming years. There are so many unexplored avenues to pursue with the real potential to provide a lasting solution for HIV/AIDS."

More information

To learn more about gene therapy, visit the Human Genome Project Information.



SOURCES: Ronald Mitsuyasu, M.D., director of the University of California, Los Angeles Center for Clinical AIDS Research and Education; Rowena Johnston, Ph.D., vice president of research, Foundation for AIDS Research, New York City. Feb. 15, 2009, Nature Medicine, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
2. Device aims to decrease wait period for patients needing immunotherapy
3. URAC Calls for Public Comment on Revisions to its Pharmacy Benefit Management (PBM) and Drug Therapy Management (DTM), Version 2.0 Standards and NEW Performance Measures, and PHARM Core, Version 3.0 Standards
4. Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation
5. Male Hormone Replacement Therapy Optimism for 2009
6. PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
7. Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma
8. Penn Medicine presents HIV gene therapy trial data at CROI 2009
9. Physiotherapy Associates Appoints Daniel J. Connors Chief Executive Officer
10. New Occupational Therapy School and Career Resource on All Allied Health Schools
11. Stroke therapy window might be extended past nine hours for some
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a family managed ... throughout the California Central Valley, is announcing a joint charity initiative with the Boys ... a local kid’s camp event. , The Boys and Girls Club of Kern County ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold and Mabel Beckman ... Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, Ph.D. - Cornell ... Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih Sarioglu, Ph.D. - ...
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon ... the importance of prostate cancer screenings. Early detection of the disease, he says, can ... surgery at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) ...
(Date:5/19/2017)... (PRWEB) , ... May 18, 2017 , ... CloSYS products ... for being non-irritating while extremely helpful for mouth and gum health, which is linked ... their professionals and customers learned quickly of the powerful ways in which CloSYS products ...
(Date:5/19/2017)... Santa Clara, CA (PRWEB) , ... May 18, 2017 , ... ... feature that allows sleep labs and physicians to independently dispense CPAP devices and supplies, ... DME orders, and sleep labs can dispense the devices. Device registration for daily usage ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
(Date:5/9/2017)... May 9, 2017  Semler Scientific, Inc. (OTCQB: ... solutions to improve the clinical effectiveness and efficiency ... the first quarter ended March 31, 2017. ... our customers to identify when preventive care options ... events like heart attacks or strokes occur," said ...
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
Breaking Medicine Technology: